

1 Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven
2 immune activation in Sjögren's Disease.

3 Sarthak Gupta^{1†}, Eiko Yamada^{2†}, Hiroyuki Nakamura³, Paola Perez², Thomas J.F. Pranzatelli³,
4 Kalie Dominick², Shyh-Ing Jang², Mehdi Abed², Daniel Martin⁴, Peter Burbelo⁴, Changyu Zheng⁴,
5 Ben French³, Ilias Alevizos², Zohreh Khavandgar^{2,5}, Margaret Beach⁵, Eileen Pelayo⁵, Brian
6 Walitt⁵, Sarfaraz Hasni¹, Mariana J. Kaplan^{1,6}, Mayank Tandon², M. Teresa Magone⁷, David E.
7 Kleiner⁸, John A. Chiorini³, Alan N. Baer⁵, Blake M. Warner^{2,5†^}

8 †These authors contributed equally to this work.

9 ^ - lead and supervised this work

10

11 1. Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin
12 Diseases, National Institutes of Health, Bethesda MD, USA.

13 2. Salivary Disorder Unit, National Institute of Dental and Craniofacial Research, National
14 Institutes of Health, Bethesda, MD, USA.

15 3. Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial
16 Research, National Institutes of Health, Bethesda, MD, USA.

17 4. Genomics and Computational Biology Core, National Institute of Dental and Craniofacial
18 Research, National Institutes of Health, Bethesda, MD, USA.

19 5. NIDCR Sjögren's Disease Clinic, National Institute of Dental and Craniofacial Research,
20 National Institutes of Health, Bethesda, MD, USA.

21 6. Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin
22 Diseases, National Institutes of Health, Bethesda MD, USA.

23 7. Consult Services Section, National Eye Institute, National Institutes of Health, Bethesda MD,
24 USA.

25 8. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National
26 Institutes of Health, Bethesda MD, USA.

27

28 Please address correspondence to:

29 (A) Sarthak Gupta (sarthak.gupta@nih.gov)

30 (B) Eiko Yamada (eiko.yamada@nih.gov)

31 (C) Blake M. Warner (blake.warner@nih.gov)

32

33 **Word Count:** 3994 (< 4000 words)

34 **Number of Tables:** 0

35 **Number of Figures:** 7

36 **References:** 48

37

38 **Abstract**

39 **Objectives:** Inflammatory cytokines that signal through the JAK- STAT pathway, especially
40 interferons (IFNs), are implicated in Sjögren’s Disease (SjD). Although inhibition of JAKs is
41 effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signaling
42 and effect of JAK inhibitor (JAKi) therapy in SjD-affected human tissues has not been reported.

43 **Methods:** Human minor salivary glands (MSGs) and peripheral blood mononuclear cells
44 (PBMCs) were investigated using bulk or single cell (sc) RNA sequencing (RNAseq),
45 immunofluorescence microscopy (IF), and flow cytometry. *Ex vivo* culture assays on PBMCs and
46 primary salivary gland epithelial cell (pSGEC) lines were performed to model changes in target
47 tissues before and after JAKi.

48 **Results:** RNAseq and IF showed activated JAK-STAT pathway in SjD MSGs. Elevated IFN-
49 stimulated gene (ISGs) expression associated with clinical variables (e.g., focus scores, anti-SSA
50 positivity). scRNAseq of MSGs exhibited cell-type specific upregulation of JAK-STAT and ISGs;
51 PBMCs showed similar trends, including markedly upregulated ISGs in monocytes. *Ex vivo*
52 studies showed elevated basal pSTAT levels in SjD MSGs and PBMCs that were corrected with
53 JAKi. SjD-derived pSGECs exhibited higher basal ISG expressions and exaggerated responses to
54 IFN β , which were normalized by JAKi without cytotoxicity.

55 **Conclusions:** SjD patients’ tissues exhibit increased expression of ISGs and activation of the JAK-
56 STAT pathway in a cell type-dependent manner. JAKi normalizes this aberrant signaling
57 at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both
58 glandular and extraglandular symptoms. Predicated on these data, a Phase Ib/IIa randomized
59 controlled trial to treat SjD with tofacitinib was initiated.

60

61 **Key messages** (total 3-5 sentences)

62 **What is already known on this topic?**

- 63 • Upregulation of interferons (IFNs) has been reported in patients with SjD; however, a
64 systematic investigation of their role at a cellular and tissue level in humans is lacking.

65 **What this study adds?**

- 66 • Our findings conclusively show that the IFN-JAK-STAT pathway is activated in the
67 salivary glands and PBMCs in patients with SjD
- 68 • Specific cells in the MSGs (infiltrating lymphocytes, epithelial, antigen presenting cells,
69 and endothelial cells) and in PBMCs (monocytes, NK cells, and dendritic cells) drive this
70 IFN signature.
- 71 • We pinpoint cells responsive to JAK inhibition and illustrate in patient tissues that JAK
72 inhibitors may be beneficial in SjD by uncoupling the pathogenic cytokine milieu and
73 resultant epithelial tissue damage and dysfunction central to SjD.

74 **How this study might affect research, practice, or policy?**

- 75 • SjD lacks an approved, efficacious and targeted therapy. Several large clinical trials have
76 been unsuccessful due in part to a lack of biologically relevant endpoints or predictive
77 biomarkers. We establish a multimodal testing platform using human tissues from SjD
78 patients to identify actionable targets and to directly test treatment effects. Our data suggest
79 that blocking the IFN-JAK-STAT pathway by using JAKi is a rational therapy for SjD.
80 Moreover, these data can also serve as biological endpoints for clinical trials
81 [NCT04496960].

82

83 **Keywords** (< 5): Sjögren's Disease, Interferon, Janus kinases, STAT, Tofacitinib

84 **Introduction**

85 Despite being the second most common systemic autoimmune rheumatic disease,
86 Sjögren’s Disease (SjD) lacks a precise etiology or an approved and efficacious therapy that
87 meaningfully manages symptoms or alters disease progression.¹ Concerted efforts have been
88 expended toward identifying the pathogenic mechanisms of SjD; these efforts have led to the
89 development and testing of many medications to treat SjD.² However, few agents met their primary
90 endpoints until very recently, and only limited biological data accompany these studies.²

91 One of the reasons for these limitations could be the heterogeneous clinical presentation of
92 patients with SjD. Chronic inflammatory lymphocytic infiltration of the exocrine glands leading
93 to dysfunction and ultimate destruction of the tissue is characteristic of SjD. Most SjD patients
94 present with symptoms involving the salivary and lacrimal glands. Other tissues that can be
95 affected include: the skin; the respiratory tract nervous system, kidneys, and the vagina, along with
96 systemic symptoms including fatigue, widespread musculoskeletal pain, and polyarthritis.^{3 4}

97 Many of the inflammatory cytokines implicated in SjD pathogenesis, in particular Type-I
98 and Type-II interferons (IFNs), interleukins (IL)-6, IL-7, IL-12, and IL-21, signal through the
99 Janus Kinases (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway.⁵
100 However, a comprehensive understanding of IFN signaling and the involvement of the JAK-STAT
101 pathway in SjD tissues is lacking. Clarification of cell types driving disease pathogenesis in the
102 peripheral blood and in the salivary glands will facilitate the development of targeted therapies for
103 SjD.

104 In this study, we aimed to characterize JAK-STAT pathway utilization in SjD-affected
105 tissues and establish a human-tissue-based experimental rationale for examining the efficacy of
106 JAK inhibitors (JAKi) in SjD participants. We used an ‘omics’ platform to identify high-potential

107 tractable pathways in the affected tissue compartments in SjD. We first performed ‘bulk’ RNA
108 sequencing (RNAseq) on minor salivary glands (MSGs) from patients with SjD and demonstrated
109 activation of the JAK-STAT pathway. These findings were corroborated using immunofluorescent
110 staining (IF) of salivary glands, and flow cytometry analysis of the salivary glands and peripheral
111 blood mononuclear cells (PBMCs) from patients with SjD. Using single cell RNAseq (scRNAseq),
112 we were able to identify cells in the glands and peripheral blood that upregulate IFNs through the
113 JAK-STAT pathway in MSGs and then confirmed these findings using flow cytometry and *ex vivo*
114 culture assays. Finally, we used patients’ tissues and primary cell models to show that JAKi can
115 correct this altered pathway activation without cytotoxicity as a high-potential targeted therapy for
116 SjD.

117

118 **Materials and Methods**

119 *Subjects and ethical approval*

120 Study subjects provided informed consent prior to the initiation of any study procedure,
121 and they were evaluated and classified comprehensively according to 2016 American College of
122 Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification
123 criteria.⁶ Comparator group included subjects who did not meet 2016 ACR-EULAR criteria (non-
124 SjD) or healthy volunteers (HV).⁷ All subjects were screened for evidence of systemic
125 autoimmunity and received comprehensive oral/sialometric, rheumatological, and
126 ophthalmological investigations. Clinical investigations were conducted in accordance with the
127 Declaration of Helsinki principles. All studies using human samples were approved by the NIH
128 IRB (15-D-0051, NCT00001390; 11-D-0172, NCT02327884, or 94-D-0018, NCT00001196; PI-
129 Warner).

130 ***Patient and Public Involvement***

131 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
132 plans of our research.

133 ***Human Salivary Gland RNA Sequencing***

134 Bulk RNA sequencing was performed as previously described.⁸ RNAseq data that passed quality
135 control was deposited in dbGaP: phs001842.v1.p1.

136 ***Single Cell RNA Sequencing of the MSGs and PBMCs***

137 MSG biopsies and PBMCs were processed for scRNAseq as previously described (**supplemental**
138 **table 1**).^{9 10} scRNAseq data sets were analyzed in Python using Scanpy.

139 ***Immunofluorescence microscopy and analysis on MSGs***

140 *Detection of JAK1 and JAK3 in MSG.* FFPE MSG sections were processed following standard
141 procedures. Sections were blocked, incubated in antibodies, and mounted (**supplemental table 2**).

142 *Immunofluorescence in primary cell culture assays.* Primary salivary gland epithelial cells
143 (pSGECs) were plated on chamber slides and stimulated as indicated, then stained with antibodies
144 (**supplemental table 2**). Images were acquired on Nikon A1 HD (Nikon) confocal microscope
145 and processed with CellProfiler in ImageJ (Broad Institute).¹¹

146 ***Flow cytometry***

147 Freshly biopsied MSGs were dissociated as described above. Multicolor flow cytometry was used
148 to quantify the phosphorylation status of pSTATs in gated cell subset populations (**supplemental**
149 **table 2** and **supplemental method 1, 2**).

150 ***Assessment of serum proteome***

151 Proteomic profiles were measured in serum (50 μ L) using the SOMAscan Assay V1.3 (SomaLogic,
152 Inc.) at the Trans-NIH Center for Human Immunology, Autoimmunity, and Inflammation,
153 National Institutes of Health as previously reported.¹²

154 ***RNA isolation and RT-qPCR***

155 Standard Taqman assays (**supplemental table 3**) were performed to measure relative gene
156 expression.

157 ***Statistical Analysis for Difference in Immune Cell Populations/Cytokines***

158 Statistical methods were employed using GraphPad Prism (GraphPad), MATLAB, or -R as
159 described, and the type and nature of the data were considered when assessing differences in mean
160 values and variances across biological and experimental replicates. A *p*-value of <0.05 was
161 considered statistically significant.

162

163 **Results**

164 ***Genes in the JAK-STAT and Type-I IFN pathways are upregulated in MSGs from patients with***

165 ***SjD***

166 To understand the transcriptome wide impacts of SjD on the MSGs, we first performed
167 ‘bulk’ RNAseq on SjD and HV MSGs (**figure 1A**). Unsupervised clustering generally segregated
168 SjD from HV MSGs based on differentially expressed genes (DEGs) (**figure 1B, C**). MSGs from
169 SjD subjects were transcriptionally more active. Immune pathway genes, including ISGs (e.g.,
170 *IFI44L, IFI44, MX1, CXCL13*), were upregulated in SjD whereas canonical salivary genes were
171 downregulated (**figure 1B, C**). Pathway enrichment analysis identified the *JAK-STAT Pathway* as
172 one of the top significantly and differentially utilized pathway in SjD (**figure 1D**). Gene
173 enrichment analysis showed consistent and direct regulation of the JAK-STAT pathway signaling

174 through *IL7/IL15/IL21* via *JAK3* (**supplemental figure 1B**). We examined the mRNA expression
175 of JAK genes and found that *JAK1* had the highest expression in all MSGs whether they were from
176 SjD or HV. However, when comparing MSGs from SjD to those from HV, *JAK2* and *JAK3*, but
177 not *JAK1* or *TYK2*, expression was differentially increased (**supplemental figure 1C**).

178 Although the bulk RNAseq was unable to reliably detect Type-I IFN transcripts, these data
179 demonstrated increased *IFNG* (**supplemental figure 1D**). Thus, we employed surrogate readouts
180 of Type-I and Type-II IFN gene expression using validated composite Type-I (21-gene)^{13 14} and
181 Type-II (8-gene)¹⁵⁻¹⁷ IFN scores to demark patients with enhanced JAK-STAT pathway signaling.
182 Calculated Type-I and Type-II IFN scores¹⁸ revealed 2-fold and 2.5-fold mean increases,
183 respectively, in SjD patients' MSGs compared to HV glands ($p=0.0033$ and $p=0.0009$,
184 respectively; **figure 1E, G**). Of the 24 SjD subjects, 17 (71%) had elevated Type-I or Type-II ISG
185 scores; 7 exhibited elevations in both Type-I and Type-II IFN ISGs; while 5 each exhibited
186 elevated Type-I or Type-II ISGs. Seven did not show significant elevation of either and were
187 enriched for anti-SSA antibody negative subjects (5/7) (**figure 1E, G**). Type-I and Type-II ISG
188 scores exhibited modest, positive, statistically significant correlation, but not all the variance was
189 explained.

190 Increased lymphocytic infiltration, quantified as a focus score (FS), is an independent
191 predictor of deterioration of exocrine gland function.¹⁹ SjD is related to both loss of epithelial cells
192 and greater inflammation in the glands. The Type-I and Type-II IFN scores from our bulk RNAseq
193 positively correlated with FS in the glands; however, Type-II IFN exhibited a stronger correlation
194 than Type-I IFN ($R^2=0.24$, $p=0.0031$ and $R^2=0.65$, $p<0.0001$, respectively; **figure 1F, H**). Our
195 data suggests that Type-II IFN signature serves as a surrogate for IFN γ produced by T cells in the
196 glands; while Type-I IFN signaling is appreciably more disease-specific and integrates the

197 contributions of the epithelial cells, dendritic cells, and monocytes in the MSG. Moreover, it is
198 well-documented that there is positive crosstalk between Type-I IFNs (α and β) and Type-II IFN
199 (γ) receptor signaling. In our cohort most patients exhibited elevated Type-I signaling. Thus, we
200 focused on Type-I signaling in subsequent experiments, acknowledging that signaling *in vivo/in*
201 *situ* is far more complex.

202 These findings confirm that SjD pathogenesis involves IFN-JAK-STAT pathway.
203 However, “bulk” RNAseq does not precisely and robustly predict the compositional cell types or
204 infer the cell states changes contributing to these phenomena in SjD-affected MSG.

205

206 *Expression of JAK1 and JAK3 in the salivary glands is cell type-specific*

207 To pinpoint the cell types and expression levels of JAK1 and JAK3 in the MSG, we used
208 IF, whole slide imaging and analysis, and tSNE visualization (**figure 2A**). These results revealed
209 the expected cellular proportion changes in the MSGs. Keratin-18 expression was restricted to
210 epithelial structures (+6%, $p < 0.001$; **figure 2B, C** and **supplemental figure 2A-C**). Per-cell JAK1
211 expression was mildly elevated in immune cells in SjD, while per-cell JAK3 expression showed
212 both SjD-specific increased per-cell expression in epithelial cells and infiltrating immune cells in
213 SjD (+35%, $p < 0.0001$ and +15%, $p < 0.0001$, respectively; **figure 2C**). It is generally assumed that
214 high IFN signaling is driven by infiltration of immune cells; however, the IF and RNAseq results
215 independently confirm that signaling is directed in part by the involved epithelium.

216

217 *Increased phosphorylated STAT proteins in SjD MSGs confirm activation of JAK-STAT* 218 *pathway*

219 To directly confirm the activation status of the JAK-STAT pathway in MSGs, we measured
220 the frequency of pSTAT proteins by flow cytometry in freshly biopsied and dissociated MSGs
221 (**figure 2A**). In general, flow cytometry exhibited cellular proportion changes consistent with the
222 IF results in the glands (**figure 2D**). The frequency of pSTAT1, pSTAT3(Ser727) and pSTAT6
223 proteins were higher at baseline in SjD epithelial cells compared to non-SjD (2.0-fold, $p=0.017$;
224 2.9-fold, $p=0.028$; and 6.9-fold, $p=0.1080$, respectively; **figure 2E**), directly supporting elevated
225 activation of the JAK-STAT pathway in SjD epithelial cells. Moreover, the frequency of pSTAT
226 proteins on immune cells showed a similar pattern in SjD-affected MSGs (1.4-fold, $p=0.3749$; 2.6-
227 fold, $p=0.068$; and 1.2-fold, $p=0.3499$, respectively; **figure 2E**), with appreciably less significant
228 differences.

229
230 ***High IFN signature and activated JAK-STAT pathway in SjD MSGs is due to salivary gland***
231 ***epithelial and infiltrating immune cells***

232 Our results implicate coordinated interactions between the epithelium and the immune
233 infiltrate (i.e., autoimmune epithelitis).³ To better understand the transcriptional impact of SjD on
234 each cell type, we then analyzed single cell transcriptomes from MSGs from SjD and non-SjD
235 subjects. Leiden clustering of scRNAseq data identified 11 clusters of cells representing the
236 general cell types in the MSGs (**figure 3A** and **supplemental figure 3A, C**). Expectedly, compared
237 to non-SjD MSGs—and consistent with both the IF and flow cytometry results—the proportion of
238 seromucous acinar cells was reduced and immune cell infiltration was increased in SjD (**figure**
239 **3B**). Examining the top ten DEGs in each of the cell types demonstrated that SjD cells were
240 dominated by ISGs (**figure 3C**). A Type-I IFN score was calculated for all cells in SjD and non-
241 SjD and was increased in all cells in SjD patients' glands (**figure 3D**). Moreover, seromucous

242 acinar cells showed increased expression of multiple *JAK* genes, while ductal cells had increased
243 expression of *JAK3* and *TYK2* (**figure 3E** and **supplemental figure 3C, D**). These results
244 independently confirm our bulk and proteomics data and suggest that disease-specific utilization
245 of this pathway in unique cell types.

246

247 *Sera from SjD have increased IFN Signature*

248 As a prototypic systemic autoimmune disease, additional non-exocrine organs are also
249 commonly affected in SjD. To estimate proteomic changes in the circulation, Somalogic aptamer-
250 based 1.3K target proteomics was performed. Most proteins were significantly upregulated in sera
251 from SjD patients compared to controls (**figure 4B**). Consistent with MSGs data, inflammation
252 and IFN regulated proteins were upregulated in sera. A validated 4-protein IFN score demonstrated
253 a significant increase of IFN-stimulated proteins in SjD patients' sera compared to both non-SjD
254 and HV sera ($p < 0.0001$; **figure 4C**). These data indicate that IFN signatures in the glands are
255 recapitulated in the blood and suggest similar pathogenic mechanisms affecting both tissue
256 compartments.²

257

258 *scRNA of PBMCs identify cells with activated JAK-STAT pathway*

259 To better understand the transcriptional impact of SjD on each cell type in the peripheral
260 blood, single-cell transcriptomes from PBMCs from SjD and non-SjD subjects were analyzed.
261 scRNAseq identified 10 unique general types by Leiden clustering (**figure 4D** and **supplemental**
262 **figure 4A, B**). DEG analysis showed upregulation of many ISGs (e.g., *IFI44L*, *IFIT3*, *ISG15*, *MX1*,
263 and *IFI6*) in SjD PBMCs (**supplemental figure 4C**). Functional annotation analysis revealed that
264 upregulated genes were mostly associated with immune and inflammatory responses, especially

265 ‘innate immunity against virus’ and ‘Type-I IFN responses’ (**figure 4E**). Type-I IFN scores were
266 projected on to each cell and were higher in SjD PBMCs compared to controls (**figure 4F**).
267 Monocytes had the highest expression of ISGs in SjD, followed by dendritic cells, and then NK
268 cells (**figure 4F**).

269

270 *Increased phosphorylated STAT proteins in SjD PBMCs confirmed activation of JAK-STAT* 271 *pathway in blood*

272 To directly estimate the activation of the JAK-STAT pathway in the blood, the frequencies
273 of pSTAT proteins were measured by flow cytometry of PBMCs from patients with SjD and HVs.
274 The frequencies of basal pSTAT proteins, pSTAT1, pSTAT3(Ser727) and pSTAT6, were higher
275 in SjD patients compared to HVs (2.0-fold, $p=0.007$, 2.3-fold, $p=0.046$, and 1.3-fold, $p=0.044$,
276 respectively; **figure 5** and **supplemental figure 5**). Of note, pSTAT3(Ser727), but not
277 pSTAT3(Tyr705) was significantly upregulated in SjD patients. In aggregate, these findings
278 indicate that enhanced Type-I IFN response in PBMCs could be involved in both the systemic
279 aspect of SjD and local inflammation after infiltration into the MSGs. Our results suggest that we
280 could employ this tissue as a surrogate model for assessing if identified drugs are biologically
281 effective for SjD or stratify patients amenable to pathway targeting, *a priori*.

282

283 *Tofacitinib inhibits Type-I IFN response in PBMCs*

284 Based on our transcriptomic and proteomic data, SjD pathogenesis may be selectively
285 dependent on JAK3 and JAK1 in both immune and epithelial compartments. Thus, we tested the
286 effectiveness of the JAK3/JAK1 semi-selective inhibitor, tofacitinib, in *ex vivo/in vitro* assays
287 (**figure 6A**). Treatment with 5 μ M tofacitinib blocked STATs phosphorylation status induced by

288 IFN β stimulation in PBMCs in all cell subsets without inducing cytotoxicity (**figure 6B** and
289 **supplemental figure 6A, D**). scRNAseq showed that 5 μ M tofacitinib downregulated 109 DEG,
290 nearly all of which were ISGs, and no genes were upregulated. Tofacitinib suppressed the IFN β -
291 induced IFN signature to baseline levels (**figure 6C, D** and **supplemental figure 6B**). Cell clusters
292 with sufficient number of representation of samples and cells in each treatment group cluster were
293 analyzed for top DEG by pseudobulk analysis. T cells and monocytes exhibited greater numbers
294 of downregulated ISGs in the context of tofacitinib inhibition. ISGs were among the top DEG in
295 all subsets after IFN β stimulation and tofacitinib normalized this response; cell type-specific
296 effects were less dominant (**figure 6E**). A similar direction of effect was shown in PBMCs treated
297 with 5 μ M tofacitinib without IFN β stimulation, though there was appreciable inter-individual
298 variability in responsiveness to tofacitinib (**supplemental figure 6C**). These data provide clear
299 and direct evidence, using affected human tissues from SjD patients, that *in vitro* tofacitinib can
300 abrogate basally activated JAK-STAT signaling and suggest that responsiveness to JAK inhibition
301 is somewhat SjD-selective. These results raised the question as to whether a similar correction
302 could be achieved in glandular epithelial cells.

303

304 ***Tofacitinib, a JAK inhibitor, reduces Type-I IFN response in primary salivary gland epithelial***
305 ***cells***

306 To model the glandular epithelial response to Type-I IFN and blockade by tofacitinib, we
307 used primary salivary gland epithelial cells derived and cultured from SjD and HV. Tofacitinib at
308 5 μ M concentration did not induce apoptosis or necrosis in pSGEC (**supplemental figure 7A, B**).
309 Tofacitinib mitigated IFN β -induced pSTAT1 proteins in both the nucleus and cytosol in pSGECs
310 as assessed by IF (0.78-fold, $p < 0.0001$; 0.84-fold, $p < 0.0001$, respectively; **figure 7B**), and dose-

311 dependently decreased IFN β -induced ISGs mRNA expression (*CXCL10*: 0.002-fold, $p=0.023$;
312 *ISG15*: 0.03-fold, $p=0.003$; *MX1*: 0.01-fold, $p=0.009$; **figure 7C** and **supplemental figure 7C**).
313 Of note, SJD-derived pSGECs exhibited an enhanced response to IFN β stimulation (e.g., *CXCL10*:
314 33.6-fold, $p=0.032$; **figure 7C**). pSGECs treated with tofacitinib without IFN β stimulation showed
315 a trend towards decreased expression of ISGs, though this was not statistically significant
316 (**supplemental figure 7D**). These results suggest that *i*) responsiveness to JAK inhibition is
317 activation-dependent and SJD-selective, and *ii*) while activation is not retained in pSGECs *in vitro*,
318 pSGECs do retain SJD-specific enhanced responsiveness to IFN stimulation²⁰ supporting the
319 robustness of this model system.

320 **Discussion:**

321 Current strategies for managing SjD are ineffective in limiting disease progression or
322 preventing the long-term decline in quality of life. Recent successes of early stage randomized
323 controlled trials in SjD (BAFF-R, TACI, CD40, CD40L²¹) offer renewed optimism to patients and
324 providers. Given the multiple intersecting pathogenic pathways driving varied clinical
325 presentations in SjD, and a paucity of successful trials, there is continued need for biologically
326 relevant, effective, and targeted therapeutics. Rational repurposing of approved drugs offers an
327 exciting path to accelerate the approval of safe and effective medications for patients with SjD. To
328 this end, we established a multimodal testing platform using human tissues from SjD patients to
329 identify actionable targets and to directly test biological effects. Specifically, we hone-in on Type-
330 I IFN signaling through the JAK-STAT pathway.

331 The activation of the IFN pathway in SjD patients' peripheral blood has been reported²²,
332 but the specific cell types driving this upregulation in blood or in the glands remain poorly detailed.
333 Using transcriptomic and functional approaches on peripheral blood and MSG tissue from SjD
334 patients, our data revealed enhanced IFN signaling via JAK-STAT in both compartments,
335 emphasizing the therapeutic potential of this pathway. We identified cell subsets driving this
336 activated state: monocytes, NK cells and DCs in PBMCs and infiltrating immune cells and salivary
337 gland epithelial cells in MSGs. Our data confirm SjD-specific upregulation of ISGs and JAK-
338 STAT pathway in salivary glands and blood, aligning with previous reports.²³ These cytokines,
339 via Janus Kinases, initiate and enhance inflammation in SjD salivary glands.^{2 24-28} Similar to a
340 previous report, the elevated IFN signatures in MSG correlated with clinical variables including
341 focus score and enrichment in autoantibody-positive subjects.²⁹

342 To understand the upstream effects in SjD-affected MSG, we measured JAK genes and
343 protein expression in the glands at single cell resolution. Among the JAK genes expressed in the
344 MSGs, *JAK1* was most abundant and ubiquitously expressed in both SjD and non-SjD. However,
345 JAK3 mRNA and protein expression was only elevated in SjD. Using IF on MSGs, JAK1 protein
346 localized to immune and epithelial cells with a very slight increased expression (~6%) in SjD
347 immune cells likely due to increased expression in APCs as found in scRNAseq. Confirming our
348 bulk and scRNAseq data, IF showed that JAK3 protein was increased in *i*) the ductal and acinar
349 epithelium in SjD involved by focal lymphocytic inflammation, and *ii*) in inflammatory cells
350 within inflammatory foci. A previous report showed JAK1 staining in ductal cells, and to a lesser
351 extent in acinar cells, in HV and SjD patients.³⁰ We extend the understanding of JAK-STAT
352 signaling in the gland by showing the novel finding of disease-specific dependence of JAK3
353 signaling in the ductal epithelium. These data provide guidance for rational drug selection (i.e., a
354 JAK3/JAK1 targeting drug such as tofacitinib) whereby the epithelium and disease-specific
355 immune infiltrates show evidence of dependence on JAK-STAT signaling through JAK3/JAK1 in
356 SjD.

357 Deciphering the JAK-STAT pathway involvement in SjD is an exciting area of
358 investigation. We and others have demonstrated significantly increased *IL21* and IL-21-inducible
359 genes: *JAK3* and *STAT1* in SjD via RNAseq of MSGs.³¹ pSTAT1 in SjD MSG biopsies has been
360 associated with IFN- α , IFN- γ , and IL-6 stimulation.³²⁻³³ Very recently, pSTAT1 was shown to
361 confer histopathological value in MSGs with or without lymphocytic foci³⁴; however, these
362 findings are based on weak intensity immunohistochemical staining of pSTAT1 without rigorous
363 quantification. We now directly confirmed that pSTAT1 and pSTAT3(Ser727) are elevated in the
364 epithelial and immune cells in the MSGs by phospho-flow cytometry from SjD subjects. It has

365 been reported that STAT protein expression is increased in immune cells of MSG.^{32 33 35}
366 Furthermore, our transcriptomic (bulk and sc) results show that STATs gene expressions are
367 upregulated in SjD, and our proteomic data establishes that the levels of pSTATs are higher in SjD
368 MSG than controls. These data further confirm that activated JAK-STAT signaling is a potentially
369 targetable pathogenetic factor for SjD.

370 Our data supports that activation of IFN pathway in SjD is a systemic phenomenon and not
371 constrained to the salivary glands.³⁶ Enhanced IFN response in PBMCs could be involved in both
372 the systemic features of SjD and local inflammation after infiltration into MSGs. T cells could
373 proliferate locally in the salivary glands, but much of their infiltration is from migration from the
374 circulation.³⁶ In PBMCs from SjD subjects, pSTAT1 frequency was significantly higher compared
375 to controls and was more of a general phenomenon across multiple cell subsets. On the other hand,
376 pSTAT3(Ser727), but not -(Tyr705), were more frequently phosphorylated in SjD T cells, NK
377 cells, and monocytes (**supplemental figure 5**). pSTAT3(Ser727) has been suggested to contribute
378 to oxidative phosphorylation in the mitochondria with an effect that is independent of
379 STAT3(Tyr705) phosphorylation.³⁷ Davies et al.³⁸ showed increased responses from B cells in
380 peripheral blood from patients with SjD to TLR-7 and -9 agonism were dependent upon
381 phosphorylation of STAT3 at the Ser727 site. It has been reported that Tyr705 phosphorylation is
382 essential for STAT dimerization, nuclear translocation and DNA binding, whereas C-terminal
383 Ser727 phosphorylation is required for maximal transcriptional activity.³⁹ The increased response
384 was found to be correlated with Type-I IFN signature suggesting that pSTAT3(Ser727) plays a
385 key role in IFN signaling in SjD patients and could be a potential molecule for targeted therapy or
386 to monitor therapeutic effects of targeted therapies. These results support *i*) the independence of

387 Ser727 from Tyr705 on pSTAT3, and *ii*) possibly highlight patients with maximal pathway
388 activation who may benefit from JAKi.

389 JAKi have emerged as an important new class of oral therapy for several autoimmune
390 diseases.^{40 41} Tofacitinib was the first oral JAK inhibitor approved for rheumatoid arthritis. It
391 blocks JAK3 and JAK1 but also has a role in JAK2 and TYK2 inhibition.⁴²⁻⁴⁶ Our *ex vivo*
392 experiments using pSGECs and PBMCs consistently demonstrated that tofacitinib treatment
393 suppressed JAK-STAT pathway activation in a dose-dependent manner, as shown by
394 downregulated pSTAT levels, decreased IFN signature and ISG expression. Of note, basal
395 elevations in pSTAT levels were selectively controlled by tofacitinib in SjD patients' PBMCs, but
396 not controls. Similar to our results, recently baricitinib, a semi-selective inhibitor of JAK1 and
397 JAK2, mitigated IFN- γ -induced CXCL10 production in salivary gland ductal cell line.³⁰

398 Cell type differences in responsiveness have been reported with regards to the potency of
399 JAKi to inhibit cytokine signaling. A 3-fold difference was observed in the JAK1/TYK2-
400 dependent IFN-stimulated pSTAT1 between CD4+ T cells and monocytes, whereas the potencies
401 were comparable for B and NK cells.⁴⁷ For the reactivity of each pSTAT, JAK inhibition of
402 JAK1/TYK2-mediated IFN α -driven pSTAT5 and pSTAT3 was more potent than pSTAT1,
403 potentially demonstrating the reliance on TYK2 for regulating STAT1 phosphorylation.⁴⁸ In our
404 study, pSTATs (e.g., pSTAT1, pSTAT3(Ser727), pSTAT6) in T cells showed consistent
405 sensitivity to JAKi treatment. Other cell subsets also demonstrated pSTAT specific sensitivity (B
406 cells – pSTAT1; NK cells–pSTAT1/6). Our findings suggest that pathogenic inflammatory
407 signaling through specific JAKs may identify selective therapeutic drug choice.

408 Limitations of this study include relatively modest sample sizes used for fresh tissue
409 analyses. The prospective use of fresh tissues poses logistical challenges including recruitment and

410 adequate tissue recovery for both clinical and research purposes. Despite these limitations, we
411 demonstrate biologically meaningful changes in JAK-STAT pathway in glandular and peripheral
412 blood samples and direct responsiveness to JAKi. These limitations are addressed by using
413 multiple different experimental approaches to systematically and comprehensively evaluate the
414 IFN-JAK-STAT pathway in SjD.

415 In conclusion, SjD patients have increased IFN signature with activated JAK-STAT
416 pathway which plays a key role in both the glandular and extraglandular pathogenesis of SjD. This
417 activation is cell specific, with salivary epithelial cells and infiltrating immune cells driving the
418 bulk of this signature in MSGs. The activated IFN-JAK-STAT signature is also seen in peripheral
419 blood, highlighting the dysregulated systemic immune system in SjD. Modulation of the JAK-
420 STAT pathway, through JAKi was non-cytotoxic and effective *ex vivo* using human tissues. These
421 results suggest tofacitinib as a potential therapeutic strategy for SjD patients and serve as the basis
422 of an open and enrolling Phase Ib/IIa randomized controlled trial to treat SjD with tofacitinib
423 (NCT04496960).

424 **Potential Conflicts of Interest:** BMW has Cooperative Research Award and Development
425 Agreements [CRADA] from Pfizer, Inc., and Mitobridge, Inc. (A subsidiary of Astellas Pharma,
426 Inc.). NIAMS has CRADAs with Astra Zeneca and Bristol Myers Squibb. These CRADA did not
427 financially support the experimental results presented herein.

428

429 **Funding/Support:** This research was principally supported through research awards to BMW
430 from the Division of Intramural Research (DIR) Program of the National Institute of Dental and
431 Craniofacial Research of the National Institutes of Health (NIH/NIDCR ZIA: DE000704).
432 Additional funding and support from the DIR Program of the National Institute of Arthritis and
433 Musculoskeletal and Skin Diseases of the NIH (NIH/NIAMS ZIA: AR041199).

434

435 **Acknowledgements:** The authors provide their emphatic appreciation to the subjects for their
436 unwavering support of our clinical studies through their volunteerism. We also thank the support
437 and staff of the NIDCR Office of the Clinical Director, NIDCR Dental Clinic, the National Eye
438 Institute Ophthalmology Clinic, and the NCI Center for Cancer Research Anatomic Pathology.

439 References

- 440 1. Mavragani CP, Moutsopoulos HM. Sjögren's syndrome: Old and new therapeutic targets. *J*
441 *Autoimmun* 2020;110:102364. doi: 10.1016/j.jaut.2019.102364 [published Online First:
442 20191209]
- 443 2. Hall JC, Baer AN, Shah AA, et al. Molecular Subsetting of Interferon Pathways in Sjögren's
444 Syndrome. *Arthritis Rheumatol* 2015;67(9):2437-46. doi: 10.1002/art.39204
- 445 3. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. *Clin Immunol Immunopathol*
446 1994;72(2):162-5. doi: 10.1006/clin.1994.1123
- 447 4. Mariette X, Criswell LA. Primary Sjögren's Syndrome. *N Engl J Med* 2018;378(10):931-39.
448 doi: 10.1056/NEJMcp1702514
- 449 5. Gandolfo S, Ciccia F. JAK/STAT Pathway Targeting in Primary Sjögren Syndrome.
450 *Rheumatol Immunol Res* 2022;3(3):95-102. doi: 10.2478/rir-2022-0017 [published
451 Online First: 20221020]
- 452 6. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European
453 League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A
454 Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.
455 *Arthritis Rheumatol* 2017;69(1):35-45. doi: 10.1002/art.39859 [published Online First:
456 20161026]
- 457 7. Warner BM, Baer AN, Lipson EJ, et al. Sicca Syndrome Associated with Immune Checkpoint
458 Inhibitor Therapy. *Oncologist* 2019;24(9):1259-69. doi: 10.1634/theoncologist.2018-
459 0823 [published Online First: 20190417]
- 460 8. Jang S-I, Tandon M, Teos L, et al. Dual function of miR-1248 links interferon induction and
461 calcium signaling defects in Sjögren's syndrome. *eBioMedicine* 2019;48:526-38. doi:
462 10.1016/j.ebiom.2019.09.010
- 463 9. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med*
464 2021;27(5):892-903. doi: 10.1038/s41591-021-01296-8 [published Online First:
465 20210325]
- 466 10. Yin H, Pranzatelli TJF, French BN, et al. Sclerosing Sialadenitis Is Associated With Salivary
467 Gland Hypofunction and a Unique Gene Expression Profile in Sjögren's Syndrome. *Front*
468 *Immunol* 2021;12:699722. doi: 10.3389/fimmu.2021.699722 [published Online First:
469 20210730]
- 470 11. Stirling DR, Swain-Bowden MJ, Lucas AM, et al. CellProfiler 4: improvements in speed,
471 utility and usability. *BMC Bioinformatics* 2021;22(1):433. doi: 10.1186/s12859-021-
472 04344-9 [published Online First: 20210910]
- 473 12. Candia J, Cheung F, Kotliarov Y, et al. Assessment of Variability in the SOMAscan Assay.
474 *Sci Rep* 2017;7(1):14248. doi: 10.1038/s41598-017-14755-5 [published Online First:
475 20171027]
- 476 13. Yao Y, Higgs BW, Morehouse C, et al. Development of Potential Pharmacodynamic and
477 Diagnostic Markers for Anti-IFN- α Monoclonal Antibody Trials in Systemic Lupus
478 Erythematosus. *Hum Genomics Proteomics* 2009;2009 doi: 10.4061/2009/374312
479 [published Online First: 20091117]
- 480 14. Gupta S, Tatouli IP, Rosen LB, et al. Distinct Functions of Autoantibodies Against Interferon
481 in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine
482 Autoantibodies in Common Rheumatic Diseases. *Arthritis Rheumatol* 2016;68(7):1677-
483 87. doi: 10.1002/art.39607

- 484 15. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. *Arthritis Res*
485 *Ther* 2003;5(6):279-87. doi: 10.1186/ar1015 [published Online First: 20031013]
- 486 16. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a
487 subgroup of systemic lupus erythematosus patients with distinct serologic features and
488 active disease. *Arthritis Rheum* 2005;52(5):1491-503. doi: 10.1002/art.21031
- 489 17. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature
490 in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci U S A*
491 2003;100(5):2610-5. doi: 10.1073/pnas.0337679100 [published Online First: 20030225]
- 492 18. Smith MA, Chiang CC, Zerrouki K, et al. Using the circulating proteome to assess type I
493 interferon activity in systemic lupus erythematosus. *Sci Rep* 2020;10(1):4462. doi:
494 10.1038/s41598-020-60563-9 [published Online First: 20200310]
- 495 19. Haldorsen K, Moen K, Jacobsen H, et al. Exocrine function in primary Sjögren syndrome:
496 natural course and prognostic factors. *Ann Rheum Dis* 2008;67(7):949-54. doi:
497 10.1136/ard.2007.074203 [published Online First: 20071025]
- 498 20. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role
499 in health and disease. *Nat Rev Immunol* 2020;20(6):375-88. doi: 10.1038/s41577-020-
500 0285-6 [published Online First: 20200304]
- 501 21. Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren
502 syndrome. *Nature Reviews Rheumatology* 2021;17(8):475-86. doi: 10.1038/s41584-021-
503 00634-x
- 504 22. Marketos N, Cinoku I, Rapti A, et al. Type I interferon signature in Sjögren's syndrome:
505 pathophysiological and clinical implications. *Clin Exp Rheumatol* 2019;37 Suppl
506 118(3):185-91. [published Online First: 2019/08/04]
- 507 23. Nordmark G, Alm GV, Rönnblom L. Mechanisms of Disease: primary Sjögren's syndrome
508 and the type I interferon system. *Nat Clin Pract Rheumatol* 2006;2(5):262-9. doi:
509 10.1038/ncprheum0173
- 510 24. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjögren's
511 syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjögren's
512 related lymphomagenesis. *J Autoimmun* 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002
513 [published Online First: 20150714]
- 514 25. Soret P, Le Dantec C, Desvaux E, et al. A new molecular classification to drive precision
515 treatment strategies in primary Sjögren's syndrome. *Nat Commun* 2021;12(1):3523. doi:
516 10.1038/s41467-021-23472-7 [published Online First: 20210610]
- 517 26. Ha YJ, Choi YS, Kang EH, et al. Increased expression of interferon- λ in minor salivary
518 glands of patients with primary Sjögren's syndrome and its synergic effect with
519 interferon- α on salivary gland epithelial cells. *Clin Exp Rheumatol* 2018;36 Suppl
520 112(3):31-40. [published Online First: 2017/04/20]
- 521 27. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary
522 Sjögren's syndrome: a possible etiopathogenic mechanism. *Arthritis Rheum*
523 2005;52(4):1185-95. doi: 10.1002/art.20998 [published Online First: 2005/04/09]
- 524 28. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid
525 dendritic cell recruitment in target organs of primary Sjögren's syndrome. *Proc Natl Acad*
526 *Sci U S A* 2006;103(8):2770-5. doi: 10.1073/pnas.0510837103 [published Online First:
527 20060213]
- 528 29. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity
529 define the origin of interferon signatures in target tissues in rheumatic diseases. *Proc Natl*

- 530 *Acad Sci U S A* 2012;109(43):17609-14. doi: 10.1073/pnas.1209724109 [published
531 Online First: 20121008]
- 532 30. Aota K, Yamanoi T, Kani K, et al. Inhibition of JAK-STAT Signaling by Baricitinib Reduces
533 Interferon- γ -Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
534 *Inflammation* 2021;44(1):206-16. doi: 10.1007/s10753-020-01322-w
- 535 31. Chen X, Jiang S, Zhou Z, et al. Increased expression of interleukin-21-inducible genes in
536 minor salivary glands are associated with primary Sjögren's syndrome disease
537 characteristics. *Rheumatology (Oxford)* 2021;60(6):2979-89. doi:
538 10.1093/rheumatology/keaa695
- 539 32. Wakamatsu E, Matsumoto I, Yasukochi T, et al. Overexpression of phosphorylated STAT-
540 1alpha in the labial salivary glands of patients with Sjögren's syndrome. *Arthritis Rheum*
541 2006;54(11):3476-84. doi: 10.1002/art.22176
- 542 33. Pertovaara M, Silvennoinen O, Isomäki P. Cytokine-induced STAT1 activation is increased
543 in patients with primary Sjögren's syndrome. *Clin Immunol* 2016;165:60-7. doi:
544 10.1016/j.clim.2016.03.010 [published Online First: 20160317]
- 545 34. Zheng Q, Liu L, Wang B, et al. Phosphorylated signal transducer and activator of
546 transcription proteins 1 in salivary glandular tissue: an important histological marker for
547 diagnosis of primary Sjögren's syndrome. *RMD Open* 2023;9(1) doi: 10.1136/rmdopen-
548 2022-002694
- 549 35. Vartoukian SR, Tilakaratne WM, Seoudi N, et al. Dysregulation of the suppressor of
550 cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the
551 aetiopathogenesis of Sjögren's syndrome. *Clin Exp Immunol* 2014;177(3):618-29. doi:
552 10.1111/cei.12377
- 553 36. Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. *J*
554 *Autoimmun* 2012;39(3):229-33. doi: 10.1016/j.jaut.2012.05.019 [published Online First:
555 20120617]
- 556 37. Reich NC. STAT3 revs up the powerhouse. *Sci Signal* 2009;2(90):pe61. doi:
557 10.1126/scisignal.290pe61 [published Online First: 20090929]
- 558 38. Davies R, Sarkar I, Hammenfors D, et al. Single Cell Based Phosphorylation Profiling
559 Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary
560 Sjögren's Syndrome. *Front Immunol* 2019;10:281. doi: 10.3389/fimmu.2019.00281
561 [published Online First: 20190221]
- 562 39. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and
563 thoracic malignancies: implications for future therapeutic approaches. *Drug Resist Updat*
564 2010;13(3):67-78. doi: 10.1016/j.drug.2010.04.001 [published Online First: 20100514]
- 565 40. Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to
566 clinical practice. *Rheumatology (Oxford)* 2019;58(Suppl 1):i4-i16. doi:
567 10.1093/rheumatology/key432
- 568 41. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases.
569 *Ann Rheum Dis* 2013;72 Suppl 2(0 2):ii111-5. doi: 10.1136/annrheumdis-2012-202576
- 570 42. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. 2017
- 571 43. Xeljanz (tofacitinib) prescribing information. 2022
- 572 44. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus
573 placebo in rheumatoid arthritis. *N Engl J Med* 2012;367(6):508-19. doi:
574 10.1056/NEJMoa1112072

- 575 45. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis.
576 *N Engl J Med* 2014;370(25):2377-86. doi: 10.1056/NEJMoa1310476
- 577 46. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy,
578 tofacitinib with methotrexate, and adalimumab with methotrexate in patients with
579 rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head,
580 randomised controlled trial. *Lancet* 2017;390(10093):457-68. doi: 10.1016/s0140-
581 6736(17)31618-5 [published Online First: 20170616]
- 582 47. Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical
583 inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib
584 and baricitinib. *Ann Rheum Dis* 2021;80(7):865-75. doi: 10.1136/annrheumdis-2020-
585 219012 [published Online First: 20210319]
- 586 48. Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are
587 blocked by pharmacological stabilization of the TYK2 pseudokinase domain. *Sci Transl*
588 *Med* 2019;11(502) doi: 10.1126/scitranslmed.aaw1736
- 589

590 **Figure Legends**

591 **Figure 1: Bulk sequencing of minor salivary gland and IFN signature**

592 (A) Overview of MSG biopsy and whole transcriptomic analysis using RNAseq from 22 SjD and
593 11 HV. (B) Heatmap illustrating the top 250 DEGs in MSG between SjD and HV highlighting
594 multiple ISGs, cytokines, and interleukins, in the DEG. Immune pathway genes, including ISGs
595 (e.g., *IFI44L*, *IFI44*, *MX1*, *CXCL13*), were upregulated whereas canonical salivary genes (e.g.,
596 *BPIFB2*, *PIP*, *ZG16B*) were down regulated in SjD. (C) Similarly, a volcano plot showing the
597 DEGs between SjD and HV, in which some representative genes were highlighted. MSGs from
598 SjD subjects were transcriptionally more active with 2773 upregulated versus 468 downregulated
599 genes. (D) Pathway enrichment analysis identified JAK-STAT Pathway as one of the top three
600 differentially utilized pathway amongst the 25 significantly enriched pathways in SjD at a p -
601 $adj < 0.01$ (E, G) Calculated Type-I and Type-II IFN scores revealed 2 through 2.5-fold mean
602 increases in SjD MSGs compared to HV. Differences in mean values were compared using the
603 Mann-Whitney U-test at a $p < 0.05$ deemed significant. (F, H) The activated IFN signature noted
604 in our bulk RNAseq positively correlated with FS in the glands. Spearman correlation analysis was
605 used to assess the significance between correlated values at a $p < 0.05$. MSG, minor salivary gland;
606 RNAseq, RNA sequencing; SjD, Sjogren's Disease; HV, healthy volunteer; DEGs, differentially
607 expressed genes; ISG, interferon stimulated genes; FS, focus score.

608

609 **Figure 2: Immunofluorescence microscopy**

610 (A) Overview of MSG biopsy, image acquisition and flow cytometry. (B) MSG IF image showing
611 upregulated expression of JAK1 and JAK3 in SjD epithelial and infiltrating immune cells. JAK3
612 was especially enrich in ductal cells. Cellular proportion changes in the SjD MSGs showed greater

613 numbers of immune cells, less numbers of epithelial cells. (C) Mean fluorescence of KRT18, JAK1
614 and JAK3 in SjD and non-SjD showing cellular proportion in the MSGs. Expression of JAK1
615 localized to immune cells (+6%; $p < 0.0001$, Mann-Whitney Test) but JAK3 expression was seen
616 in both epithelial and infiltrating immune cells (35% and 15%, respectively; $p < 0.0001$, Mann-
617 Whitney Test). (D) Cellular population change in 7 SjD and 6 non-SjD was characterized by flow
618 cytometry showed reduced numbers of epithelial cells and increased numbers of infiltrating
619 immune cells in SjD MSGs compared to controls. (E) Flow cytometry of MSG represented the
620 frequency of pSTAT proteins: pSTAT1 (2.1-fold, $p = 0.017$), pSTAT3(Ser727) (2.2-fold, $p = 0.031$),
621 and pSTAT6 (3.3-fold, $p = 0.112$) were higher at baseline in SjD epithelial cells compared to non-
622 SjD. Although not reaching the threshold of statistical significance, the frequency of pSTAT
623 proteins (i.e., pSTAT3(Ser727) ($p = 0.056$)) on CD45+ cells showed a similar frequency of pSTAT
624 proteins in the SjD MSG. P value was calculated using Welch's test. MSG, minor salivary gland;
625 IF, immune fluorescent; SjD, Sjogren's Disease; KRT18, Keratin-18.

626

627 **Figure 3: Single cell RNAseq and pSTATs frequencies of MSG**

628 (A) UMAP embedding of the entire dataset colored by generated clusters labelled by cell type
629 annotation. From all profiled MSG samples from 7 SjD and 5 non-SjD, Leiden clustering identified
630 11 different cell clusters corresponding to mucous (*MUC5B*) and seromucous acinar cells (*MUC7*),
631 ductal cells (*SI00A2*), plasma cells (*IGHA*, *IGHG1*), fibroblasts (*COL1A2*), myoepithelial
632 (*KRT14*), pericytes (*ACTA2*), B-cells (*CD79A*), antigen presenting cells (*HLA-DRA*, *CD68*), T-
633 lymphocytes (*CD3D*), and erythrocytes (*HBB*) (n=51736 cells). (B) Differential of cell density
634 showing increased immune cell infiltration in SjD. (C) The top ten DEG in each of the cell types
635 were dominated by ISGs including increased expression *B2M*, *HLA-B*, *SAA1*, *IL32*, and *MGP*. (D)

636 Differential expression of IFN score in SjD and non-SjD, immune cells showed the biggest fold-
637 changes in IFN score were in infiltrating immune cells (e.g., plasma cells: 700-fold, APCs: 400-
638 fold; T cells: 300-fold; seromucous cells: 250-fold; ductal epithelial cells: 250-fold) exhibited
639 higher IFN scores. (E) Fold change expression of JAK-STAT genes on all cell types. *JAK1* was
640 the most ubiquitously expressed in MSGs and Seromucous acinar cells showed increased
641 expression of all *JAKs*. UMAP, Uniform manifold approximation and projection; MSG, minor
642 salivary gland; SjD, Sjogren's Disease; DEG, differentially expressed genes.

643

644 **Figure 4: Single cell RNaseq and pSTATs frequencies of PBMC**

645 (A) Overview of using patient's serum and PBMC for several assays. (B) Somalogic aptamer-
646 based 1.3K target proteomics analysis revealed most of proteins were significantly upregulated in
647 serum from SjD in volcano plot showing protein expression, in which some representative genes
648 were highlighted. (C) IFN regulated proteins were found to be upregulated in SjD serum
649 ($p < 0.0001$). P value was calculated using Kruskal-Wallis test. (D) UMAP embedding of the entire
650 dataset colored by generated clusters labelled by cell type annotation. Leiden clustering identified
651 10 different cell clusters from all profiled PBMC samples from 8 SjD and 6 non-SjD ($n=206687$
652 cells). (E) The upregulated genes were associated with immune and inflammatory responses
653 revealed by functional annotation analysis from PBMC scRNaseq. (F) Differential expression of
654 IFN score, monocytes had the highest expression of ISGs, followed by dendritic cells and then NK
655 cells. SjD, Sjogren's Disease; UMAP, Uniform manifold approximation and projection; RNaseq,
656 RNA sequencing; ISG, interferon stimulated genes.

657

658 **Figure 5: Basal pSTATs frequencies in PBMCs**

659 (A-D) Flow cytometry analysis revealed basal pSTATs levels in PBMCs were upregulated in 21
660 SjD compared to 10 HV. P value was calculated using Welch's test. SjD, Sjogren's Disease; HV,
661 healthy volunteer.

662

663 **Figure 6: Treatment effects of tofacitinib in PBMCs**

664 (A) Overview of using PBMC treated by tofacitinib for scRNAseq and FACS. PBMCs were
665 treated with or without 5mM tofacitinib for 1 hour prior to IFN β treatment for 30 minutes or 6
666 hours, respectively. (B) Treatment with tofacitinib blocked STATs phosphorylation status induced
667 by IFN β stimulation in PBMCs from SjD. P value was calculated using Mann-Whitney test. (C)
668 UMAP embedding of the entire dataset colored by generated clusters labelled by 4 general cell
669 type annotations. (D) Differential utilization of IFN signature of each condition showed tofacitinib
670 abolished the IFN β -induced IFN score to baseline level. (E) Volcano plot showing DEGs by
671 pseudobulk analysis across SjD and HV, in which some representative genes were highlighted. T
672 cells (129 genes) and monocytes (61 genes) exhibited greater numbers of downregulated ISGs in
673 the context of tofacitinib. ISGs (e.g., *IFIT1*, *IFIT3*) were among the top DEG in all subsets after
674 IFN β and tofacitinib normalizing this response. RNAseq, RNA sequencing; SjD, Sjogren's
675 Disease; DEG, differentially expressed genes; HV, healthy volunteer; ISG, interferon stimulated
676 genes.

677

678 **Figure 7: Treatment effects of tofacitinib in pSGECs**

679 (A) Overview of using pSGEC treated by tofacitinib for IF and RT-qPCR. pSGEC were derived
680 from fresh MSG biopsies. (B, C) Differential expression of pSTAT1 in pSGECs. Tofacitinib
681 treatment mitigated IFN β -induced STAT1 phosphorylation in both the nucleus and cytosol. P

682 value was calculated using Kruskal-Wallis test. (D) Expression change of ISGs (*i.e.*, *CXCL10*,
683 *ISG15*, *MX1*) on pSGECs showing dose-dependently decreased IFN β -induced ISGs mRNA
684 expression. 5 SjD and 5 HV (n=5 individuals' lines, respectively). 1 SjD and 1 HV samples were
685 eliminated from MX1 result. P value was calculated using Mann-Whitney test and Kruskal-Wallis
686 test. pSGEC, primary salivary gland epithelial cells; SjD, Sjogren's Disease; HV, healthy
687 volunteer; ISG, interferon stimulated genes.











Figure 1





Figure 2

D



E




Figure 2




Figure 4








Figure 6



A**B**

Figure 7



C**D**

Figure 7